All AbMole products are for research use only, cannot be used for human consumption.
MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. Treatment with MBX-2982 increased insulin, active GLP-1, and total GLP-1 during an extended MMTT. Treatment with MBX-2982 also tended to increase fasting insulin and c-peptide, and decrease fasting triglycerides. MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
Molecular Weight | 448.54 |
Formula | C22H24N8OS |
CAS Number | 1037792-44-1 |
Solubility (25°C) | DMSO ≥ 10 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Jones RM, et al. Expert Opin Ther Pat. GPR119 agonists for the treatment of type 2 diabetes.
Related GPR/FFAR Products |
---|
GPR84 antagonist 8
GPR84 antagonist 8 is a selective GPR84 antagonist. |
ML191
ML-191 is an antagonist of GPR55. |
CID1172084
CID1172084 is a selective GPR55 agonist (EC50=0.16 μM). |
ML 145
ML 145 is a selective and competitive human GPR35/CXCR8 antagonist with an IC50/EC50 of 20.1 nM. |
PSN 375963 hydrochloride
PSN 375963 hydrochloride is a potent GPR119 agonist, with EC50s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.